GOSS
Gossamer Bio Inc.
Company Overview
| Mkt Cap | $564.75M | Price | $0.17 |
| Volume | 23.42M | Change | -6.15% |
| P/E Ratio | -3.3 | Open | $0.20 |
| Revenue | $48.5M | Prev Close | $0.18 |
| Net Income | $-170.4M | 52W Range | $0.14 - $3.87 |
| Div Yield | N/A | Target | $3.80 |
| Overall | 38 | Value | 40 |
| Quality | 31 | Technical | 45 |
No chart data available
About Gossamer Bio Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Latest News
Gossamer Bio Announces Final Convertible Notes Exchange Results
Vanguard Total Stock Market (VTI) ETF Daily Update — June 16, 2026
Gossamer Bio shareholders reaffirm board and governance structure
Gossamer Bio Restructures Capital Through Convertible Notes Exchange
Gossamer Bio Extends Early Deadline in Note Exchange
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GOSS | $0.17 | -6.1% | 23.42M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |